Geriatrik Hematoloji Derne\u011fi Kurucu Ba\u015fkan\u0131 \u0130lhan, AA muhabirine yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, ya\u015fl\u0131 n\u00fcfusta kanser g\u00f6r\u00fclme s\u0131kl\u0131\u011f\u0131 ve g\u00fcncel tedavi \u00e7al\u0131\u015fmalar\u0131na ili\u015fkin bilgileri payla\u015ft\u0131.<\/p>\n
Hematolojik kanserlerin \u00f6zellikle 65 ya\u015f \u00fcst\u00fcnde g\u00f6r\u00fclme s\u0131kl\u0131\u011f\u0131n\u0131n artt\u0131\u011f\u0131n\u0131 s\u00f6yleyen \u0130lhan, bu ya\u015f gruplar\u0131nda en s\u0131k Hodgkin D\u0131\u015f\u0131 Lenfoma (HDL), multipl miyelom, Kronik Lenfositer L\u00f6semi (KLL) ile akut l\u00f6semilerin g\u00f6r\u00fcld\u00fc\u011f\u00fcn\u00fc anlatt\u0131.<\/p>\n
![\"\"](\"https:\/\/www.aa.com.tr\/uploads\/userFiles\/de89f914-66b1-4a0b-9347-13c0eafe70cc\/2023%2F04%2F20230407_2_58135711_87658409.jpg\"\/)
<\/p>\n
Prof. Dr. \u0130lhan, “65 ya\u015f alt\u0131nda 100 binde 1 olan hematolojik kanserler, 65 ya\u015f \u00fcst\u00fcnde maalesef 20-30 kat artarak 100 binde 30 oran\u0131na \u00e7\u0131k\u0131yor. T\u00fcrkiye’de 9 milyona ula\u015fan 65 ya\u015f \u00fcst\u00fc n\u00fcfusu dikkate ald\u0131\u011f\u0131m\u0131zda 2023’te yeni hematolojik kanser te\u015fhisi alacak vatanda\u015f say\u0131s\u0131 20 binden fazla. Bizlerin buna hem tan\u0131 hem de tedavi anlam\u0131nda haz\u0131r olmas\u0131 gerekiyor.” diye konu\u015ftu.<\/p>\n
“Stres de kanser oranlar\u0131n\u0131n artmas\u0131nda etkili”<\/h3>\n
Ortalama \u00f6m\u00fcr s\u00fcresinin uzamas\u0131n\u0131n, kanser g\u00f6r\u00fclme oranlar\u0131n\u0131 da art\u0131rd\u0131\u011f\u0131na i\u015faret eden \u0130lhan, “Ayr\u0131ca sigara kullan\u0131m\u0131, sa\u011fl\u0131ks\u0131z beslenme, obezite, hareketsiz ya\u015fam, artan stres ve geneti\u011fiyle oynanm\u0131\u015f g\u0131dalar da kanser oranlar\u0131n\u0131n artmas\u0131nda etkili. \u00d6zellikle kan kanserlerinin beklentinin de \u00fczerinde art\u0131\u015f g\u00f6sterece\u011fini d\u00fc\u015f\u00fcn\u00fcyoruz.” ifadesini kulland\u0131.<\/p>\n
\u0130lhan, karbonhidrat ve ya\u011fdan az, sebze ve meyveden zengin beslenme, paketli g\u0131dalardan uzak durma ve d\u00fczenli egzersizin ileri ya\u015flarda kansere yakalanmama a\u00e7\u0131s\u0131ndan b\u00fcy\u00fck \u00f6nem ta\u015f\u0131d\u0131\u011f\u0131n\u0131 vurgulad\u0131.<\/p>\n
“Ge\u00e7en y\u0131l 1000’den fazla hastaya k\u00f6k h\u00fccre nakli yap\u0131ld\u0131”<\/h3>\n
T\u00fcrkiye’de sosyal devlet anlay\u0131\u015f\u0131yla kanser tedavilerinin \u00fccretsiz oldu\u011funu an\u0131msatan \u0130lhan, “\u00d6rne\u011fin, ge\u00e7en y\u0131l devlet ve \u00f6zel hastanelerde 1000’den fazla multipl miyelom hastas\u0131na k\u00f6k h\u00fccre nakli yap\u0131ld\u0131.” dedi.<\/p>\n
30 y\u0131ld\u0131r yap\u0131lan “ABD Hematoloji Kongresi”nin ge\u00e7en aylarda d\u00fczenlendi\u011fini ve T\u00fcrk bilim insanlar\u0131 olarak, bu kongrede yer ald\u0131klar\u0131n\u0131 aktaran \u0130lhan, g\u00fcncel tedavilerin ele al\u0131nd\u0131\u011f\u0131n\u0131 dile getirdi.<\/p>\n
“2030’lu y\u0131llarda art\u0131k kesin tedaviden bahsedebilece\u011fiz”<\/h3>\n
Prof. Dr. \u0130lhan, \u015fu de\u011ferlendirmelerde bulundu:<\/p>\n
“Multipl miyelom tedavisinde ge\u00e7en senelerde sadece bir monoklonal antikor kullan\u0131l\u0131rken art\u0131k bunlar\u0131n ikili, \u00fc\u00e7l\u00fc hedefe y\u00f6nelik olanlar\u0131 ortaya \u00e7\u0131kt\u0131, hedefe y\u00f6nelik, ki\u015file\u015ftirilmi\u015f tedaviler d\u00f6nemi ba\u015flad\u0131.<\/p>\n
Hastal\u0131\u011f\u0131n k\u00f6kten \u00e7\u00f6z\u00fcm\u00fc i\u00e7in de CAR-T dedi\u011fimiz h\u00fccresel tedaviler yayg\u0131nla\u015f\u0131yor. Miyelom kanserine yol a\u00e7an ana h\u00fccreye y\u00f6nelik tedaviler \u00f6n\u00fcm\u00fczdeki d\u00f6nemlerde daha \u00e7ok kar\u015f\u0131m\u0131za \u00e7\u0131kacak, yayg\u0131nla\u015facak. 2030’lu y\u0131llarda art\u0131k kesin tedaviden bahsedebilece\u011fiz.”<\/p>\n
\u0130lhan, T\u00fcrkiye’de de bu yeni tedavilerin g\u00fcndeme gelece\u011finin alt\u0131n\u0131 \u00e7izerek, “Ben 45 y\u0131ll\u0131k bir doktorum ve \u00fclkemiz hematoloji alan\u0131nda bug\u00fcn gelinen noktada uluslararas\u0131 alanda da \u00f6nc\u00fc durumda. 2030’da hematolojik kanserler, \u00f6zellikle multipl miyelomada h\u00fccresel tedavilerin k\u00f6kten \u00e7\u00f6z\u00fcm sa\u011flayaca\u011f\u0131na inan\u0131yorum.” \u015feklinde konu\u015ftu.<\/p>\n